Skip to content

Author

Yan-Qing Wu

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Real-world safety of vericiguat as a fifth-line agent in heart failure: a pharmacovigilance study of quintuple therapy

Background Vericiguat, a novel soluble guanylate cyclase (sGC) stimulator, is indicated for high-risk worsening heart failure (HF). However, its real-world reporting profile when added to contemporary quadruple guideline-directed medical therapy (GDMT)—effectively creating a “quintuple” regimen—remains largely unexplor...

Da-Qiu Chen, Y. Wu, Zi-Xun Wang et al. · 0 citations
Oct 2026

Repurposing the gastroprotective agent geranylgeranylacetone for atherosclerosis: a novel role of the HSP22-Nrf2-mitochondrial axis.

Mitochondrial dysfunction is a pivotal driver of vascular endothelial injury and atherogenesis. This study aimed to evaluate the therapeutic potential of geranylgeranylacetone (GGA), a clinically established gastroprotective agent, in atherosclerosis and to explore the underlying molecular mechanisms. Apolipoprotein E-...

Meng Li, Yi Chen, Zhi-Jian Wu et al. · 0 citations
Oct 2026

Stepwise dual antiplatelet therapy de-escalation versus standard therapy for 12 months in patients with bifurcation lesions undergoing drug-coated balloon angioplasty: Insights from the REC-CAGEFREE II trial.

Stepwise DAPT de-escalation may be a safe and effective strategy for ACS patients with bifurcation lesions undergoing DCB-only angioplasty and Bleeding Academic Research Consortium type 3 or 5 bleeding.

Yong-Meng Yan, Qiong Wang, Yi Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.